Norges Bank’s Cullinan Oncology CGEM Stock Holding History

Norges Bank’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-101,900	Closed	-$1.08M	–	2103
2022 Q4	$1.08M	Hold	101,900	–	–	﹤0.01%	2048
2022 Q3	$1.31M	Buy	+101,900	New	+$1.37M	﹤0.01%	1979

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Norges Bank's CGEM Position: Q1 2023 in Review

Norges Bank sold out of Cullinan Oncology (CGEM) in Q1 2023, closing a stake of 101,900 shares — an estimated $1.08M sold.

Norges Bank first reported a position in CGEM in Q3 2022 and held it in 2 quarters. The position peaked at $1.31M in Q3 2022. 103 funds tracked by Wall St. Rank hold CGEM as of Q1 2023.

Norges Bank reported no remaining Cullinan Oncology position as of Q1 2023 after selling out during the quarter.
Norges Bank sold 101,900 Cullinan Oncology shares in Q1 2023, an estimated $1.08M.
Norges Bank first reported a position in Cullinan Oncology in Q3 2022 and held it in 2 quarters.
Norges Bank's Cullinan Oncology position peaked at $1.31M in Q3 2022.
103 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2023.

Based on Norges Bank's 13F filing for Q1 2023, filed 15 May 2023.